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ABSTRACT
Objective To examine whether in vitro and ex vivo measure-
ments of topical drug product performance correlate with
in vivo outcomes, such that more efficient experimental ap-
proaches can be reliably and reproducibly used to establish
(in)equivalence between formulations for skin application.
Materials and Methods In vitro drug release through artifi-
cial membranes, and drug penetration into porcine skin
ex vivo, were compared with published human in vivo studies.
Two betamethasone valerate (BMV) formulations, and three
marketed econazole nitrate (EN) creams were assessed.
Results For BMV, the stratum corneum (SC) uptake of drug
in 6 h closely matched data observed in vivo in humans, and
distinguished between inequivalent formulations. SC uptake
of EN from the 3 creams mirrored the in vivo equivalence in
man (both clinically and via similar tape-stripping experi-
ments). However, EN clearance from SC ex vivo did not par-
allel that in vivo, presumably due to the absence of a function-
ing microcirculation. In vitro release of BMV from the different
formulations did not overlap with either ex vivo or in vivo tape-
stripping data whereas, for EN, a good correlation was ob-
served. No measurable permeation of either BMV or EN was
detected in a 6-h in vitro skin penetration experiment.
Conclusions In vitro and ex vivo methods for topical bioequiv-
alence determination can show correlation with in vivo out-
comes. However, these surrogates have understandable limi-
tations. A Bone-size-fits-al l^ approach for topical
bioequivalence evaluation may not always be successful,
therefore, and the judicious use of complementary methods
may prove a more effective and reliable strategy.
KEY WORDS dermatopharmacokinetics . in vitro release
test . in vitro skin penetration . IVIVC . topical bioequivalence
ABBREVIATIONS





Cveh Drug concentration in vehicle
EN Econazole nitrate
IVPT In vitro penetration test
IVRT In vitro release test
Jss Steady-state flux
K Stratum corneum – vehicle partition coefficient
kp Permeability coefficient
log P Logarithm of the octanol-water partition
coefficient
MCT Medium chain triglyceride
ME Microemulsion
Q6h Quantity absorbed in 6 h
SC Stratum corneum
TEWL Transepidermal water loss
INTRODUCTION
There is a pressing need to develop appropriate methods, as
alternatives to clinical endpoint studies, to determine the bio-
equivalence of topical dermatological products (1). In general,
regulatory agencies may accept different types of evidence to
establish bioequivalence based upon how complex the dosage
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form is, and how similar formulations are to each other; for
example, if solution formulations with the same amount of
active ingredient contain the same inactive ingredients in the
same amounts, then the risk of inequivalence may be consid-
ered to be inherently low. However, for semi-solid formula-
tions that differ in excipient composition or dosage form (gel
versus cream, for instance), amongst which the partitioning
and/or diffusion of the active ingredient into and across the
skin may be altered (2), it is imperative that surrogate in vitro,
ex vivo and/or in vivo methods be optimized and validated to
ensure that an effective and reliable determination of
bio(in)equivalence be obtained.
The provision of less expensive medicines is the ob-
vious driving force to identify procedures to facilitate
the commercialization of bioequivalent, generic drug
products (3, 4). With respect to oral delivery, the ac-
cepted approach is relatively straightforward and is
principally based on matching blood level profiles (rate
and extent of absorption) (5). For topical drug products
other than the corticosteroids, a clinical trial is essential-
ly and typically the only route for approval of a generic
product or for replacement of an already approved der-
matological product that has appreciable compositional
changes (3). But, comparative clinical trials are relatively
insensitive, time-consuming and costly; to gain the ade-
quate statistical power needed to clearly evaluate bio-
equivalence may require a large number (i.e., hundreds)
of subjects (6).
There is an imperative, therefore, to validate one or more
assessment approaches that might replace clinical efficacy
studies to demonstrate bioequivalence (BE). The principal
contenders for the determination of topical bioavailability
(BA) and BE are summarized in Table I andmay be separated
into in vitro and in vivo approaches. The table identifies those
methods, which have not yet received official sanction from
the U.S. Food & Drug Administration as independent means
with which to evaluate topical BA/BE, and others that have
each, to some extent, been employed to compare different
topical drug products (7).
In this study, alternative methods to evaluate topical BE are
considered for formulat ions of a cort icosteroid,
betamethasone valerate (BMV), and of an anti-fungal drug,
econazole nitrate (EN), which have previously been examined
in in vivo stratum corneum tape-stripping experiments in hu-
man volunteers (8, 9). For BMV, the formulations were pre-
pared extemporaneously and were clearly inequivalent to one
another when compared with the accepted vasoconstriction
assay (8); the stratum corneum tape-stripping results were con-
sistent with this finding. In the case of EN, the tape-stripping
data confirmed the results of clinical trials that found the three
creams examined to be bioequivalent. Here, the formulations
of the two drugs are first subjected to in vitro release testing
using model membranes, before being compared in an ex vivo
tape-stripping protocol using porcine skin samples. A limited,
but ultimately uninformative, in vitro skin penetration test
(again using excised porcine skin) was also undertaken.
MATERIALS & METHODS
Formulations
Two betamethasone valerate (BMV, Sigma-Aldrich,
Gillingham, UK) formulations were prepared, exactly as pre-
viously described (8): (a) dissolved in medium chain triglycer-
ides (MCT) (Mygliol 812 N, Synopharm, Barsbüttel,
Germany), and (b) in the microemulsion Mikro 100® (ME)
(Sebapharma, Boppard, Germany). The vehicles were thick-
ened into semi-solid gels with 6% (w/w) Aerosil® 200 (Sigma-
Aldrich). The BMV concentration in each of the two formu-
lations was adjusted to 80% of the drug’s solubility (9.3 and
1.7 mg mL−1 for ME and MCT, respectively), i.e., to provide
equivalent thermodynamic activity (8).
Similar to an earlier, detailed human in vivo tape-stripping
study (9), three, commercially available econazole nitrate (EN)
formulations (1% w/v) were considered: the reference listed
product, Fougera® (E.Fougera & Co., Melville, NY), and
two generic creams (listed as AB in the FDA Orange Book
(10)) from Perrigo (Bronx, NY) and Taro (Hawthorne, NY).
In Vitro Release Test (IVRT)
BMV and EN transport from the various formulations was
measured across either cellulose membranes (both hydrophil-
ic, lot R2SA21096, and hydrophobic, lot R6AN36175, pore
size 0.45 μm, fromWhatman, Ltd., Little Chalfont, UK), or a
non-porous silicone membrane (75 μm thickness, Dow
Corning 7-4107, Auburn, MI). The membranes were soaked
in phosphate-buffered saline (pH 7.4), containing 0.5% poly-
ethylene glycol hexadecyl ether (Brij 58®, Sigma-Aldrich) for
0.5 h before mounting in standard Franz diffusion cells. The
same solution as that used to pre-soak the membranes also
Table I Accepted and Investigational Methods for Assessing Topical Drug
Product Bioavailability/Bioequivalence
Methods for topical bioavailability/bioequivalence Currently accepted
In vitro approaches Release tests (model membranes) Yes
Skin penetration experiments No







Stratum corneum tape-stripping No
Dermal microdialysis No
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provided the receptor phase (volume = 7.4 mL) and was cho-
sen to ensure adequate drug solubility and the maintenance of
sink conditions during the experiment. The jacketed diffusion
cells were maintained at 32°C using a circulating water bath.
Post-application of the BMV and EN formulations (221 and
4.5 mg/cm2, respectively (8, 9)), which were evenly spread
over the membrane surface (2 cm2) facing the occluded donor
compartment of the Franz diffusion cell, samples of the recep-
tor phase (0.5 to 2 mL) were withdrawn at 0.25, 0.5, 0.75, 1, 2,
3, 4, 5 and 6 h for BMV, and at 0.5, 1, 2, 3, 4, 5 and 6 h for
EN, and replaced with fresh receptor solution. The cumula-
tive amount of drug released from each formulation as a func-
tion of time was assayed by high performance liquid chroma-
tography using previously described methods (8, 9).
In Vitro Skin Penetration and ex Vivo Tape-Stripping Experiments
For the in vitro permeation test (IVPT) using excised porcine
skin in Franz diffusion cells, the tested formulations were ap-
plied as in the IVRT experiments (221 and 4.5 mg/cm2 for
BMV and EN formulations respectively, both occluded). The
skin was sourced from a local abattoir, dermatomed (Zimmer
dermatome, Dover, DE) to a nominal thickness of about
750 μm and then frozen at −20°C. Before use, the tissue
was slowly thawed and mounted in the diffusion cell. The
receptor medium was 7.4 mL of phosphate-buffered saline
(pH 7.4) containing 0.5% w/v Brij 58®. Again, the jacketed
diffusion cells were maintained at 32°C using a circulating
water bath. The formulations were applied for 6 h (mimicking
the earlier in vivo study design (8, 9)) at the end of which the cell
was dismantled and the entire receptor phase contents were
reserved for analysis of permeated drug. For BMV, the skin
surface was cleaned of residual formulation either (a) by
wiping with a dry paper towel, or (b) with this dry wipe
procedure plus the use of two successive 70% v/v isopropyl
alcohol swabs (Seton Healthcare, Oldham, UK). For
EN, the skin surface cleaning procedure used only alco-
hol swabs as reported previously (9).
Subsequently, for both drugs, the skin was securely pinned
to a polystyrene board and the central area was delimited with
a template, the area of which equaled that exposed to the
formulation. The stratum corneum (SC) at this site was then
sequentially removed by adhesive tape-stripping (Scotch Book
Tape, 3 M, St. Paul, MN for BMV, Shurtape J-LAR®, Avon,
OH for EN) in accord with published procedures (2, 11).
Concomitant measurements of transepidermal water loss
(TEWL), made before and throughout the tape-stripping pro-
cess, indicated that most, if not all, of the SC was removed (by
which point TEWL had attained a value of 100 g/m2/h or
more); the number of tape-strips required to do so was be-
tween 8 and 30. The adhesive tapes were weighed on a sensi-
tive balance (Sartorius Microbalance SE-2 F, precision 0.1 μg;
Sartorius AG, Göttingen, Germany) before and after skin
stripping so that the mass of SC removed could be deter-
mined. As explained elsewhere (12–14), this information to-
gether with the corresponding change in TEWL as a function
of the increasing quantity of SC removed allows the thickness
of this barrier layer to be simply determined. The amount of
drug removed on each tape-strip was then determined by
extracting the drug from the adhesive by shaking overnight
with an appropriate volume (in both cases 1 mL) of a suitable
solvent: 40:60 v/v acetonitrile:water for BMV, pure methanol
for EN. To optimize sensitivity, tape-strips from the deeper
SC were usually analysed in groups of up to 4.
In a separate series of experiments with EN, once the skin
surface had been cleansed of residual formulation at 6 h, the
tissue was placed in an oven (maintained at 32°C; with the der-
mal side of the skin fully hydrated). After a further 17 h, the SC
tape-stripping procedure was carried out exactly as described
above. The objective of this component of the work was tomimic
the ‘clearance’ period of the earlier human in vivo study (9).
Data Analysis
IVRT
The results were presented as cumulative drug release as a
function of time, and the behaviour of the different formula-
tions compared. Themost appropriate function describing the
release profile (e.g., linear, t1/2 kinetics) was assessed.
Ex Vivo Tape-Stripping
No measurable permeation of either BMV or EN into the
diffusion cell receptor chamber was detectable in 6 h, obviat-
ing any need to interpret such data. For BMV, the drug con-
centration profile (C as a function of depth position x) across
the SC after the 6-h uptake was fitted to the solution of Fick’s
2nd law of diffusion for constant vehicle concentration (Cveh)
at the surface (x = 0) of an initially drug-free SC:
























to derive values of the SC-vehicle partition coefficient (K)
and the ratio of the drug’s SC diffusivity to the SC thickness
squared (D/L2) as explained in earlier work (11, 15).
Additionally, the permeability coefficient across the SC (kp)
and the steady-state flux (Jss) were estimated using the inde-
pendent assessment of SC thickness.
In the case of EN, a more straightforward analysis of
the results was undertaken, mirroring the approach
adopted in the published in vivo tape-stripping study per-
formed in human volunteers (9). Here, the uptake and
clearance of the drug were determined from the total
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drug amounts recovered from the SC tape-strips collected
either immediately or 17 h after cleaning.
Statistics
As the goal of this research was not to establish
bio(in)equivalence between the different formulations of
the two drugs considered, the number of replicates
employed in the in vitro and ex vivo parts of the study were
not based on rigorous power calculations. Rather, the
values of Bn^ employed were selected to match those
which had been used in the previous in vivo experiments
(n = 6 for BMV and n = 14 for EN) (8, 9).
Statistical analysis involved two-tailed Student’s t-tests and
one- and two-way analyses of variance (ANOVA) followed by
Bonferroni’s test; p-values less than 0.05 were considered sta-
tistically significant.
RESULTS
In Vitro Release Tests
IVRT with the BMV formulations revealed that no mea-
surable amount of the drug transported into the receptor
phase across the porous hydrophobic or silicone mem-
branes. BMV release was observed across the hydrophilic
membrane, however. From the microemulsion gel (ME),
1430 (±161) μg cm−2 was released in 6 h, while the cor-
responding amount from the medium chain triglyceride
formulation (MCT) was 7.7 (±0.8) μg cm−2. The large
difference in the two quantities may have been caused
by the simultaneous diffusion of surfactant from the ME
gel facilitating solubilisation of BMV in the receptor
phase. For both formulations, drug release was described
by a typical square root of time dependence.
Release of EN from all three formulations across each
of the three membranes used was detected (Fig. 1). While
the cumulative amounts released in 6 h were significantly
different depending on the membrane used (ANOVA
followed by post-hoc test), within each membrane there
was no significant difference in drug release from the
three formulations.
Ex Vivo Skin Penetration
At the end of the 6-h experiment, no BMV was found in the
receptor solution demonstrating its inability to cross the skin
regardless of the vehicle used within this short time-frame.
The samewas true for EN, a finding consistent with the earlier
in vivo tape-stripping investigation, the results of which indicat-
ed a lag-time of ~13 h (9).
Figure 2 (left panels) presents BMV concentration
profiles as a function of position within the SC, deter-
mined from the ex vivo tape-stripping experiments fol-
lowing the 6-h treatment with the gelled medium
chain triglyceride (MCT) and microemulsion (ME) gel
formulations; the skin surface was wiped clean with
dry tissue in these experiments. The data are com-
pared to the corresponding results (right panels) redrawn
from the published in vivo study conducted on human
volunteers (8).
Partitioning and apparent diffusion parameters de-
rived as described above (15) are summarized in
Fig. 3 along with the total amounts of drug taken up
into the SC at 6 h, and estimated values of the perme-
ability coefficients and apparent steady-state fluxes.
These results are again compared with those reported
from the earlier in vivo experiments (8, 9). For both
formulations, there was excellent agreement (and no sig-
nificant difference) between the ex vivo-derived parame-
ters and those from the in vivo human study; equally, as
observed from the tape-stripping experiments in human
volunteers, the uptake of BMV into the SC and the
apparent steady-state flux of the drug, were almost an
order of magnitude greater from the microemulsion
compared to the MCT formulation (8.7-fold ex vivo versus
7.2-fold in vivo).
When the ex vivo experiments were repeated with the
skin being cleaned more rigorously with isopropyl alco-
hol swabs, the Q6h values for both formulations were
reduced by about 50% (data not shown), confirming
that this approach is a more robust method with which
to remove residual formulation (16).
The ex vivo tape-stripping experiments with econazole
nitrate (EN) were undertaken using the same protocol as
that used in the published in vivo, human study (9). The
uptake and clearance of the drug from the SC were
determined in an identical number of replicates, taking
care to thoroughly cleanse the skin surface after the 6-h
exposure to the three creams and to ensure that essen-
tially all of the SC was removed in the tape-stripping
procedure. Figure 4 reports the amounts of EN recov-
ered from the SC after the 6-h uptake and subsequent
17-h clearance periods.
Analysis of variance of the results for both uptake and
clearance shows that there was no significant difference be-
tween the three formulations considered. Also noteworthy is
that for each EN cream, there was no significant difference
between the drug amounts recovered in the SC after uptake
and clearance periods. The mean values, and the upper and
lower 90% confidence intervals (C.I.) on the data obtained,
are collected in Table II.
As the uptake and clearance values were indistin-
guishable for each of the three creams tested,
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equivalence between the products was assessed using the
combined results and the ratios of [uptake + clearance]
for the mean values of the two test formulations
(Perrigo and Taro) to that of the reference (Fougera).
The calculations were undertaken using both the raw
data (Fig. 4) and the log transformed results. The out-
come was essentially identical, in terms of the ratios
falling within the conventional range of 0.8 to 1.25 (2,
17), and is summarized in Table III.
DISCUSSION
The IVRT results show distinct behaviour between the
two drugs considered. On the one hand, EN release
from the three products tested was easily measurable
across the three different artificial membranes used.
In addition, the release characteristics for the different
formulations were the same across each individual
membrane. However, the profiles did not overlap
quantitatively when comparing the data obtained from
the different membranes, and the shape of the profile
across the hydrophilic cellulose barrier was distinct
from that across the two hydrophobic membranes
(Fig. 1). For BMV, over a period of 6 h, drug release
was not measurable through the two hydrophobic
membranes, presumably reflecting the high solubility
of the drug in these barriers. In contrast, release
through hydrophilic cellulose was detectable and
proceeded with a classic square-root-of-time depen-
dence, which distinguished between the two formula-
tions tested.
The message from these experiments should be clear
and has been articulated before (18). Specifically, while
IVRT can provide useful quality control information
about the consistency of (for example) different produc-
tion batches, it is unwise to predict drug bioavailability
in v i vo , e i ther relat ive or absolute, from these
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Fig. 1 EN release (mean± SD; n=6) from three commercially available creams across three artificial membranes. Data have been staggered on the time axis
for clarity and the square root of time transformation of the results from the silicone membrane is illustrated in the lower right-hand panel of the figure.
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measurements alone. The EN data show that the
amounts released differ depending upon the membrane
employed and that the quantities ‘delivered’ across the
membranes can be substantially higher than even those
amounts which only enter the SC in the same period.
Although the apparent equivalence shown by IVRT of
the three EN products is mirrored in both in vivo and
ex vivo tape-stripping studies (and is indeed consistent
with clinical performance too), any deduced correlation
should be carefully considered in light of the results for
BMV. For this drug, in two cases, IVRT shows no
permeation of drug whatsoever. It follows, therefore,
that not only is it very unlikely that a single artificial
membrane can be used to standardize the IVRT ap-
proach for all drugs, but also, even if one did, that it
would be capable of mimicking any formulation effects
(e.g., the action of an excipient which is a penetration
enhancer) on real skin.
The ex vivo SC tape-stripping experiments with BMV
showed extremely good qualitative and quantitative
agreement with previously published (8) human in vivo
studies (Figs 2 and 3). The results demonstrate that
carefully conducted studies on excised skin (and, in this
instance, excised skin from a recognized and generally-
considered acceptable model for the human barrier (19,
20)) can be usefully predictive of the in vivo situation, as
has been intimated before (21). While it may be unlikely
that this strategy would eventually evolve into any sort
of regulatory guidance, the availability of an alternative,
ex vivo approach may be attractive in formulation devel-
opment and optimisation.
The results from the EN ex vivo tape-stripping study















































Fig. 3 Derived values (n=6, mean± SD) of BMV SC-vehicle partition
coefficients (K), diffusivity parameters (D/L2), permeability coefficients (kp)
and apparent steady-state fluxes (Jss), as well as the total drug quantities taken
up into the SC in 6 h (Q6h), following delivery from MCTand ME formula-
tions. The filled bars are results derived from the ex vivo porcine skin exper-
iments reported here; the stippled bars represent data from a published in vivo
study using the same formulations and methodology (8).
Fig. 2 BMV concentration profiles
(n=6) across porcine SC ex vivo
(left panels, this work) and across
human SC in vivo (7) (right panels)
following a 6-h application of the
drug in either a microemulsion (ME)
or a medium chain triglyceride
formulation (MCT).
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the previously published in vivo human data (9). On
the positive side, the uptake of the drug into the SC
of excised porcine skin over 6 h correlated completely
with the data in man and (correctly) demonstrated the
equivalence between the three drug products tested
(Tables II and III). In contrast, while the results from
the clearance part of the study were self-consistent in
that they also indicated the equivalence of the formu-
lations (Fig. 4), the data diverged, however, from the
earlier in vivo observations. In vivo, there was about a
30% reduction in the SC level of econazole during
the clearance phase but, ex vivo, there was no decrease
at all. The most likely and obvious explanation for
this observation is that excised skin lacks a functioning
microcirculation and fails to provide, as a result, the
sink conditions necessary to clear a very lipophilic
drug like econazole. This active moiety prefers to re-
main in the SC, therefore, and does not deplete sig-
nificantly over the 17-h period subsequent to the re-
moval of residual formulation. This implies that an
ex vivo tape-stripping approach to assess topical bio-
equivalence may not routinely furnish information on
the elimination aspect of ‘skin pharmacokinetics’, es-
pecially for drugs with high log P values. However,
this does not mean that such experiments are without
value; on the contrary, data on the uptake phase are
extremely useful for optimising the design of an in vivo
experiment and for providing valuable insight into the
performance of prototypical formulations being con-
sidered for clinical evaluation. That having been said,
suitable modifications to the protocol used here may
permit this approach to also shed light on the clear-
ance process; for example, maintaining the skin in
contact with a receptor chamber of large volume, or
with a flow-through option, and using thinner sections
of excised skin are strategies worthy of investigation.
In conclusion, the results of this investigation con-
firm that techniques, such as IVRT and SC tape-
stripping, are robust approaches with which to char-
acterise aspects of topical drug product performance
that contribute to the active pharmaceutical ingredi-
ent’s ultimate bioavailability in the skin. However,
each of the methods used here have limitations that
have been articulated above: IVRT can address fea-
tures of the formulation’s quality, but cannot report
on the manner in which the product will interact with
the skin; ex vivo tape-stripping permits good prediction
of drug uptake into the SC in vivo but, with respect to
the determination of drug clearance, careful attention
needs to be paid to the optimisation of the experi-
mental design. Because of the brevity of the experi-
ments performed, no useful information on drug per-
meation through excised skin was obtained; neverthe-
less, it is clear that classic in vitro penetration experi-
ments also have an important role to play in the ar-









































































Fig. 4 Total amounts of econazole
recovered in the SC, following
uptake and clearance periods of 6
and 17 h, respectively, in ex vivo
tape-stripping experiments (n=14)
with three commercially available
EN creams.
Table II Average Quantities (n=14) of Econazole in the SC After Uptake
and Clearance Periods Following Application of Three Drug Products,
Together with the Corresponding Upper and lower 90% Confidence inter-
vals (C.I.)
Quantity of EN (μg cm−2) Drug product
Perrigo Fougera Taro
Uptake Mean 2.19 1.81 1.77
Lower 90% C.I. 1.61 1.17 1.44
Upper 90% C.I. 4.18 3.70 2.22
Clearance Mean 1.96 2.28 2.80
Lower 90% C.I. 1.48 1.42 1.44
Upper 90% C.I. 3.23 4.24 4.88
Table III Simulated Bioequivalence Assessment, Based on Combined [up-
take + clearance] Data (n= 28), Between the Three EN Creams with
Fougera Serving as the ‘Reference product’ and Perrigo and Taro as the ‘tests’
Bioequivalence assessment Perrigo vs. Fougera Taro vs. Fougera
Average ratio (test/reference) 1.02 0.99
Lower 90% C.I. 0.89 0.87
Upper 90% C.I. 1.17 1.12
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